What Are the Challenges in Using CTLA-4 Inhibitors?
Despite their potential, CTLA-4 inhibitors are not effective for all patients. Predicting who will respond to treatment remains a significant challenge. Biomarkers such as PD-L1 expression and tumor mutational burden are being investigated to help identify patients who are more likely to benefit from these therapies. Additionally, the management of immune-related adverse events requires specialized knowledge and prompt intervention, which can complicate treatment.
